Peptide status lookup: FDA, advisory committee, WADA and evidence

Last updated October 26, 2026

Search or filter the 15 peptides we have covered, one row each. Every column answers a separate question about where a peptide stands today: has FDA approved it as a drug, can a pharmacy compound it under FDA’s category lists, what did the July 2026 advisory committee do with it, does WADA name it for tested sport, and how far has the human research gotten. A row is a set of facts, not a score, and a row cannot be added up into a verdict.

Facts are as of October 26, 2026. Fourteen of the rows are the names in our overview table, which is generated from the same data file, so the two cannot disagree. The fifteenth row, tesamorelin, is an approved drug in the same family, included as a reference point. Unfamiliar word? The glossary explains it.

Status of 15 peptides across five separate questions, as of October 26, 2026
Peptide	Approved drug?	Compoundable? (FDA 503A/503B lists)	FDA advisory committee, July 23-24, 2026 (press-reported votes)	In tested sport? (WADA 2026 list)	Human evidence record (stage marker)
BPC-157	No U.S. approval found	Nomination withdrawn; listed on FDA's category 2 page	In favor, 8-6, 1 abstention [S]	Named, S0	Early-stage research, mostly cells and animals; three small human studies in newer reviews
TB-500	No U.S. approval found	Nomination withdrawn; listed on FDA's category 2 page	In favor, 8-6, 1 abstention [S]	Named, S2.3	Early-stage research; FDA found no human exposure data
CJC-1295	No U.S. approval found	Nomination withdrawn; listed on FDA's category 2 page	Not reviewed	Named, S2.2.4	Small controlled trials in healthy adults
Ipamorelin	No U.S. approval found	503A nomination withdrawn; still category 2 for 503B	Not reviewed	Named, S2.2.4	Phase 2 surgery trial completed, well tolerated
Sermorelin	Formerly FDA-approved (1990 and 1997 products)	Category 1 on the 503B list; not on the 503A category lists	Not reviewed	Named, S2.2.4	Long human record from the approval era
AOD-9604	No U.S. approval found	Nomination withdrawn; listed on FDA's category 2 page	Not reviewed	Named, S2.2.3	Animal studies, then a human weight-loss study
MOTS-c	No U.S. approval found	Nomination withdrawn; listed on FDA's category 2 page	In favor, 7-5, 2 abstentions [S]	Named, S4.4.1	Mouse studies and human observational data
Thymosin alpha-1	Approved in several countries; no U.S. approval	503A nomination withdrawn; category 3 on 503B	Not reviewed	Not named	Long trial record, including meta-analyses
KPV	No U.S. approval found	Nomination withdrawn; listed on FDA's category 2 page	In favor, 8-6, 1 abstention [S]	Not named	Early-stage research: mouse colitis and cell studies
GHK-Cu	Cosmetic ingredient; no U.S. drug approval found	Category 1 on 503A, except injectable routes	Later agenda, before end of February 2027	Not named	Small human skin studies; a phase 2 study is recruiting
Epitalon	No U.S. approval found	Nomination withdrawn; listed on FDA's category 2 page	In favor, 7-4 or 7-5 by outlet [S]	Not named	Cell, monkey and small human biomarker studies
Selank	No U.S. approval found	Nomination withdrawn; listed on FDA's category 2 page	Not reviewed	Not named	One small Russian comparison with an active drug
Semax	Registered in Russia as nasal drops; no U.S. approval	Nomination withdrawn; listed on FDA's category 2 page	In favor, 8-5, 1 abstention [S]	Not named	Rat studies and small Russian clinical work
Dihexa	No U.S. approval found	Nomination withdrawn; listed on FDA's category 2 page	Later agenda, before end of February 2027	Not named	Early-stage research; FDA found no human exposure data
Tesamorelin	Yes, for one use (Egrifta, approved November 10, 2010)	Not on the category lists, as searched; it is the ingredient of an approved drug	Not reviewed	Named, S2.2.4	Two phase 3 trials (806 adults randomized) plus later randomized trials

Colour key (neutral facts, not grades):Approved or long human recordListed, favored, named or early human dataNeutral status factPending or later agenda

How to read it

The colours describe a status and are not grades. Green marks an approved drug or a long human record, blue marks a listing, a favorable committee vote, a WADA naming or early human data, grey marks a neutral fact, and violet marks something still pending. No chip says a peptide is safe or unsafe, and no chip is advice.

Committee votes are press-reported [S]: the FDA meeting pages and slides we read describe the agenda, and the vote counts come from news reports, so that column is labelled that way. A vote is advice to FDA, not a decision. The approval, compounding-list and WADA columns come from the primary documents linked below [V], and the evidence column uses our own stage markers, explained in the evidence ladder post.

If a row looks out of date or wrong, tell us through the corrections page. The related reading below explains each column in depth.

Sources and as-of date

Every fact above was retrieved on October 26, 2026. [V] means verified in a primary document, [S] means a secondary (press) source.

The 14 peptides at a glance, the post that explains this table in prose
FDA compounding categories explained
Peptides and the WADA Prohibited List
The evidence ladder: what research shows
Glossary and how we source

Peptide status lookup: FDA, advisory committee, WADA and evidence

How to read it

Sources and as-of date

Related reading